41 recruiting. 41 Phase 3, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 41 | Recruiting 41 |
| Phase 2 | 10 | Recruiting 10 |
Follow Behavioral Symptoms: new trials by email Literature Review of Behavioral Symptoms trials Research Report on Behavioral Symptoms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial Neuronavigated robotic-enabled TMS, NRX-101, Sham TMS - Treatment Resistant Depression, Treatment Resistant Depression (TRD) | Phase 2 / Phase 3 | Recruiting | NeuroRx, Inc. | 240 | 2026-12-01 | 2026-10-21 |
| Morphine or Ketamine for Analgesia Ketamine hydrochloride, Morphine sulphate - Abdominal Pain, Isolated Extremity Fracture | Phase 3 | Recruiting | Columbia University | 1010 | 2026-10-17 | 2026-10-20 |
| Brexanolone Lifting Outcomes Of Moms LPCN 1154A, Placebo - Depression, Postpartum, Postpartum Depression (PPD) | Phase 3 | Recruiting | Lipocine Inc. | 120 | 2026-09-01 | 2026-09-16 |
| Lumateperone for Late-Life Depression Lumateperone, Placebo - Treatment Resistant Depression (TRD), Late Life Depression (LLD) | Phase 3 | Recruiting | Eric Lenze | 100 | 2026-09-01 | 2026-09-16 |
| A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder Brenipatide, Placebo - Depressive Disorder, Major | Phase 3 | Recruiting | Eli Lilly and Company | 1000 | 2026-08-14 | 2026-11-03 |
| Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression Psilocybin - Major Depression | Phase 3 | Recruiting | VA Office of Research and Development | 240 | 2026-08-03 | 2026-10-23 |
| Allopurinol in Depression Sertraline 50 MG, Allopurinol 300 MG - Depression | Phase 2 / Phase 3 | Recruiting | Tanta University | 70 | 2026-05-20 | 2026-08-18 |
| InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression Ketamine, Oculus VR headset - Treatment Resistant Depression | Phase 3 | Recruiting | Sunnybrook Health Sciences Centre | 31 | 2026-05-03 | 2026-10-23 |
| Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth N-acetylcysteine, Mindfulness-based cognitive therapy, Placebo - Mild Depression | Phase 3 | Recruiting | University of Cincinnati | 160 | 2026-02-26 | 2026-03-11 |
| REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool Senseye Diagnostic Tool (DT), Clinician Administered PTSD Scale for DSM-5, Revised Version - PTSD - Post Traumatic Stress Disorder | Phase 3 | Recruiting | Senseye, Inc. | 1900 | 2026-02-23 | 2026-04-29 |
| A Study of Brenipatide in Adult Participants With Major Depressive Disorder Brenipatide, Placebo - Depressive Disorder, Major | Phase 3 | Recruiting | Eli Lilly and Company | 1000 | 2026-02-09 | 2026-10-05 |
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder CYB003, Psychological Support - Major Depressive Disorder (MDD), Depression in Adults | Phase 3 | Recruiting | Cybin IRL Limited | 330 | 2025-12-10 | 2026-11-02 |
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) KarXT, KarX-EC - Alzheimer Disease, Agitation | Phase 3 | Recruiting | Bristol-Myers Squibb | 650 | 2025-12-02 | 2026-10-16 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo - Alzheimer's Disease | Phase 3 | Recruiting | Bristol-Myers Squibb | 426 | 2025-07-16 | 2026-11-03 |
| Ketamine Augmentation of ECT in Treatment-Resistant Depression Ketamine Hydrochloride, Placebo - Major Depressive Disorder, Treatment Resistant Depression | Phase 3 | Recruiting | Università Vita-Salute San Raffaele | 30 | 2025-07-10 | 2026-05-11 |
| E-Mindfulness Approaches for Living After Breast Cancer Mindfulness (MAPs) Live Online, Mindfulness (MAPs) Digital App, Meditation Only Control Group - Breast Cancer, Depression | Phase 3 | Recruiting | NRG Oncology | 402 | 2025-06-27 | 2026-08-04 |
| NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) NBI-1065845, Placebo - Major Depressive Disorder | Phase 3 | Recruiting | Neurocrine Biosciences | 200 | 2025-05-30 | 2026-08-10 |
| Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) NBI-1065845 - Major Depressive Disorder | Phase 3 | Recruiting | Neurocrine Biosciences | 850 | 2025-04-16 | 2026-11-02 |
| Understanding and Treating Suicidal Ideation With Ketamine ketamine hydrochloride - Suicidal Ideation, Major Depressive Disorder (MDD) | Phase 2 / Phase 3 | Recruiting | The Royal's Institute of Mental Health Research | 36 | 2025-04-08 | 2026-05-19 |
| NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) NBI-1065845, Placebo - Major Depressive Disorder | Phase 3 | Recruiting | Neurocrine Biosciences | 200 | 2025-03-31 | 2026-08-11 |
Showing 20 of 41. Sign in to see all of them.
Depression (29) · Depressive Disorder, Major (12) · Anxiety Disorders (6) · Depressive Disorder, Treatment-Resistant (4) · Psychomotor Agitation (4) · Alzheimer Disease (3) · Mood Disorders (3) · Stress Disorders, Post-Traumatic (3) · Suicidal Ideation (3) · Depressive Disorder (2) · Emergencies (2) · Hypesthesia (2) · Paresthesia (2) · Abdominal Pain (1) · Agnosia (1)
Behavior (41) · Mental Disorders (27) · Depressive Disorder (13) · Mood Disorders (13) · Pathological Conditions, Signs and Symptoms (10) · Nervous System Diseases (9) · Neurologic Manifestations (9) · Signs and Symptoms (9) · Neurobehavioral Manifestations (7) · Aberrant Motor Behavior in Dementia (4) · Dyskinesias (4) · Psychomotor Disorders (4) · Self-Injurious Behavior (4) · Brain Diseases (3)
Ketamine (8) · Oxygen (2) · mirabegron (2) · xanomeline (2) · Acetylcysteine (1) · Allopurinol (1) · Buprenorphine (1) · Cannabidiol (1) · Cholinergic Antagonists (1) · Creatine (1) · Deamino Arginine Vasopressin (1) · Esketamine (1) · Lorazepam (1) · Midazolam (1) · Mindfulness (1)
Neurocrine Biosciences (4) · Bernardino Clavo, MD, PhD (2) · Bristol-Myers Squibb (2) · Eli Lilly and Company (2) · Sunnybrook Health Sciences Centre (2) · ACADIA Pharmaceuticals Inc. (1) · AbbVie (1) · Assistance Publique - Hôpitaux de Paris (1) · Centre Hospitalier Universitaire de Nīmes (1) · Columbia University (1) · Cybin IRL Limited (1) · Dr. Karin Hediger (1) · Eric Lenze (1) · Harmony Biosciences Management, Inc. (1) · Lipocine Inc. (1)
United States (27) · Canada (10) · Spain (8) · United Kingdom (8) · Poland (7) · Australia (6) · France (6) · Germany (6) · Italy (6) · South Korea (6) · Czechia (5) · Puerto Rico (5) · Taiwan (5) · Brazil (4) · Bulgaria (4)
Bernardino Clavo, MD, PhD (2) · Alan Peterson, PhD, ABPP (1) · Alberto AZ Zangrillo, MD (1) · Amy L Drendel, DO, MS (1) · Cristina CC Colombo, MD (1) · Daniel S Tsze, MD, MPH (1) · Eric J Lenze, MD (1) · Fabrice Jollant, MD (1) · Felix Mazer (1) · Giovanni Marotta, MD (1)
PMID 39672260, PMID 40570329, PMID 41572235
2023 (3), 2025 (3), I01RD001520 (1), R01AG082892 (1), R01AT013115 (1), R01CA282416 (1), R01MH125214 (1), U01HD116253 (1), UG1CA189867 (1), UL1TR002645 (1)